Successful community initiatives are creating systems of care that bridge multiple programs to provide coordinated services to individuals with substance use disorders. Here are five.
Here’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.
A new report from Cardinal Health Specialty Solutions gives behind-the-scenes perspectives from oncologists about CAR-T cell therapies, biosimilars and AML therapies (or genomic medicines)
Simple strategies can improve the nutritional well-being of COPD patients and help them maintain their weight.
Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.
The Innovation and Value Initiative launched the Open-Source Value Project, creating tools that help payers, providers, and healthcare systems make informed and patient-centered decisions that produce better health outcomes.
Two new studies address the financial implications of unexpected major healthcare expenses for common cardiovascular conditions and procedures.
While CAR T-cell therapy has been proven to work for liquid—or blood—cancers, the challenge has been to apply this technology to solid tumors.
A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Transplant eligibility issues and drug regimen options raise difficult questions when treating older multiple myeloma patients.